Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]
Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]
Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:
The company went into liquidation in 2019 after unsuccessful clinical trials, and failure to find a buyer for OPN-305.
Opsona's main investors were international and life-science focused:
References
- Ireland's got talent retrieved 27 February 2018^
- Sunday Business Post article retrieved 27 February 2018^
- Opsona Therapeutics Limited: Private Company Information - Bloomberg investing.businessweek.com, retrieved 27 February 2018